This is a Phase 1, open-label, multicenter study to evaluate the safety and to determine the optimal dose of bb2121 in patients with newly diagnosed multiple myeloma who are specifically considered ‘high risk’ (meaning that the disease stage and genetic testing are linked to a poor prognosis).
This trial is currently open and accepting patients.
This trial is seeking approximately 30-60 people living with newly diagnosed multiple myeloma who are specifically considered ‘high risk’ (meaning that the disease stage and genetic testing are linked to a poor prognosis) to participate.
This trial is organized into a single arm, which means that all participants are planned to receive bb2121.
This trial is organized into four parts: Pre-Treatment, Treatment, Post-Treatment, and Survival Follow-up.
Pre-Treatment – During this part of the trial, you will receive four cycles of an anti-myeloma treatment regimen. A cycle is a period of treatment followed by a period of rest (no treatment) that is repeated on a regular schedule. Participants will undergo the collection of their T cells (leukapheresis) to make into bb2121 after the third cycle of anti-myeloma therapy. The study doctor will determine which of the anti-myeloma regimens you will receive before leukapheresis.
Treatment – During this part of the trial you will receive lymphodepleting chemotherapy (chemotherapy treatment that removes some of your own immune cells, making space for the bb2121 T cells to grow in your body, and to increase the chances of your body’s ability to accept the bb2121 T cells) and bb2121. Approximately 5 days before you receive bb2121, you will receive three consecutive days of lymphodepleting chemotherapy. This is necessary to remove some of your immune cells to make room for bb2121, and to help your body to accept the bb2121 cells. When you receive bb2121, you will be hospitalized for approximately 14 days so that your study doctor can monitor you closely for side effects.
Post-Treatment - Once you are discharged from the hospital, you will need to stay within a 30 minute drive from your treating hospital and have a dedicated caregiver staying with you for the remainder of the 30 days following your bb2121 treatment. You will need to visit your study site for follow-up monthly for the first 6 months, then every 3 months for the first two years. Your study doctor may prescribe a maintenance anti-myeloma therapy like Lenalidomide for you during this time.
Follow-up – Study staff will continue to contact you approximately every 3 months to obtain information on how you are doing up until 2 years after the last patient receives bb2121. They may ask you to undergo testing to see if bb2121 cells are still present in your body, and if they have changed in any way.
There is an optional longer term follow-up safety study that may last 15 years
Phase 1
Enrollment: 60 patients (estimated)
View MoreThe following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.
View all clinical trial locations sorted by state.
Denver, CO
Read the latest news and updates on this trial.
December 05, 2020
Patients with heavily pretreated multiple myeloma maintained durable responses with the chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel (ide-cel; bb2121) in updated findings presented from the phase 1 CRB-401 trial (NCT02658929).
We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.
(888) 828-2206If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.
Find Nearby LocationsYou can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message
SparkCures is working closely with Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors